Sumary of New WHO report highlights barriers to insulin for diabetes:
- © iStock/vitapix A new report highlights the worrying state of global access to insulin for diabetes care and finds that high prices, low availability of human insulin, few producers dominating the insulin market and weak health systems are the main barriers to universal access.
- Insulin for diabetes treatment is essential for diagnosed individuals to manage their condition, reducing fatality rates, risk of kidney failure, blindness and limb amputation for people living with type 1 and type 2 diabetes.
- “The scientists who discovered insulin 100 years ago refused to profit from their discovery and sold the patent for just one dollar,” said WHO Director-General, Dr Tedros Adhanom Ghebreyesus.
- ” 100 years since the discovery of insulin One of out every two people needing insulin for type 2 diabetes does not have access to it.
- The report highlights that three in four people affected by type 2 diabetes live in countries outside of North America and Europe, but they account for less than 40% of the revenue from insulin sales.
- To commemorate the 100th anniversary of the discovery of insulin, the World Health Organisation emphasises the main causes for gaps in global access to insulins are: Global market shift from human insulin to analogues (synthetic insulin).
- Human insulin has a low cost associated with its production and analogues is more costly.
- It can be up to three times more expensive in some countries and is as effective as the cheaper alternative, human insulin.